---
schema_version: "secwatch.filing_event.v1"
accession: "0001321732-24-000086"
form_type: "8-K"
ticker: "PEN"
cik: "0001321732"
company_name: "Penumbra Inc"
filed_at: "2024-07-30T23:59:59+00:00"
generated_at: "2026-05-31T15:04:17.900624+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Penumbra Q2 revenue $299.4M (+14.5%); loss from ops $81M on $110.3M impairment charges

## Summary
- U.S. thrombectomy revenue $153.7M, up 24.9% YoY; global thrombectomy revenue $203.5M (+25.2%).
- GAAP operating loss $81.0M includes $110.3M non-cash impairment/write-down on Immersive Healthcare assets.
- Non-GAAP income from operations $31.7M vs $20.3M YoY; adjusted EBITDA $46.3M (15.5% margin).
- Cash/marketable investments increased $26.2M from Q1, driven by non-GAAP profitability and working capital.
- Global embolization & access revenue fell 3.1% YoY to $95.9M, with international down 10.8%.

## SEC filing metadata
- accession: 0001321732-24-000086
- form_type: 8-K
- ticker: PEN
- cik: 0001321732
- company_name: Penumbra Inc
- filed_at: 2024-07-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1321732/000132173224000086/0001321732-24-000086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1321732/000132173224000086/pen-20240730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001321732-24-000086
- JSON: https://secwatch.observer/filing/0001321732-24-000086.json
- Plain text: https://secwatch.observer/filing/0001321732-24-000086.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.